Subscribe To
MYGN / Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek treatment according to the GeneSight® Mental Health Monitor nationwide survey
MYGN News
By GlobeNewsWire
October 31, 2023
Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold more_horizontal
By Zacks Investment Research
September 20, 2023
Myriad Genetics (MYGN) Secures Key Milestones in Illumina Tie-Up
Myriad Genetics (MYGN) achieves significant milestones in its partnership with Illumina. more_horizontal
By Zacks Investment Research
September 19, 2023
Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform
Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer. more_horizontal
By Zacks Investment Research
September 12, 2023
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Investors are optimistic about Myriad Genetics (MYGN) on improvement in testing volume across all its businesses. more_horizontal
By Seeking Alpha
September 7, 2023
Myriad Genetics: FRα Addition Further Diversifies Portfolio
Myriad Genetics is a leading molecular diagnostic company that focuses on developing and marketing predictive, personalized, and prognostic medicine t more_horizontal
By Zacks Investment Research
August 16, 2023
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test. more_horizontal
By Zacks Investment Research
August 11, 2023
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
Myriad Genetics' (MYGN) GeneSight report will contain details on how a patient's smoking history may affect their metabolism of certain medications. more_horizontal
By Zacks Investment Research
August 7, 2023
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance. more_horizontal